Elias Zambidis, MD

Call
Website

Photos

1800 Orleans St Bldg 11TH Fl 11
Baltimore, MD 21287
+1 (410) 955-8751
https://www.hopkinsmedicine.org
Dr. Zambidis is Associate Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Zambidis’ clinical expertise is in the treatment of disorders of the immune system, histiocytic disorders, hematologic malignancies, blood and bone marrow transplantation (BMT), and regenerative medicine. His research interest focuses on advancing our understanding of pluripotent stem cells– the ‘master’ stem cells that can generate any new cell or tissue that the body needs to repair itself. Dr. Zambidis earned his M.D./Ph.D. in the Medical Scientist Training Program at the University of Rochester, Rochester, N.Y. He completed his Pediatrics Residency in the Department of Pediatrics, Washington University, St. Louis, Missouri, and his clinical/research fellowships in Pediatric Hematology/Oncology at the Johns Hopkins Hospital and the National Cancer Institute at the NIH. Dr. Zambidis has been interested in the biology of stem cells since he came to Johns Hopkins, in 2001. As a Pediatric Hematology/Oncology fellow, he was one of the very first Hopkins investigators to work with human embryonic stem cells (hESCs), beginning shortly after they were made available to the biomedical research community, in 2002. Dr. Zambidis was awarded the first NIH K08 Clinician-Scientist Training Award specifically investigating the therapeutic potential of human pluripotent stem cells (2004). After joining the Hopkins faculty, in 2005, he developed an experimental model of the early formation process of human blood and blood vessels using human pluripotent stem cells.The Zambidis laboratory at the Johns Hopkins Institute for Cell Engineering focuses on understanding the developmental biology of human hemato-vascular and human pluripotent stem cells. More recently, his group completed studies on highly efficient methods for generating nonintegrated, human induced pluripotent stem cell (hiPSC) lines from myeloid progenitors. His group has developed novel hiPSC-based vascular therapies for retinopathies, and more recently derived a new class of human pluripotent stem cells in a naïve ground state with new functionalities with even greater potency and stronger regenerative capacities. As a BMT physician-scientist, his long-term goal is to use hESC, hiPSC, and related pluripotent stem cell technologies to not only treat severe degenerative diseases, but also to elucidate the biological nature of cancer and aging.
Request an Appointment

Also at this address

Owner verified
See a problem?

You might also like

Stacy L. Cooper, MD
Internal medicine practitioners

Stacy L. Cooper, MD

Dr. Stacy Cooper is the Director of the Pediatric Hematologic Malignancy Program, Director of the Pediatric Hematology/Oncology Fellowship Program, and Clinical Director of the Pediatric Oncology Inpatient Program at the Johns Hopkins School of Medicine. Dr. Cooper received her undergraduate degree in Biology and Spanish at the University of Notre Dame. She earned her M.D. at SUNY Upstate Medical University. She completed her general pediatric residency and chief residency at the Johns Hopkins School of Medicine. She completed her pediatric hematology-oncology fellowship with the Johns Hopkins-National Institutes of Health. Dr. Cooper joined the Johns Hopkins faculty in 2015. Her research focuses on clinical research in acute lymphoblastic leukemia, as well as medical education scholarship related to fellowship training. Dr. Cooper is a member of the American Board of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology Oncology and the Association of Pediatric Program Directors.
Donald Small, MD
Internal medicine practitioners

Donald Small, MD

Dr. Donald Small is the Kyle Haydock Professor of Oncology. He holds joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He also directs the Johns Hopkins/National Cancer Institute Pediatric Hematology/Oncology Fellowship program. Dr. Small received his undergraduate, and then M.D. and Ph.D. degrees from the Johns Hopkins University in 1979 and 1985. His Ph.D. research was conducted with Bert Vogelstein in the Oncology Department and his postdoctoral research with Tom Kelly in the Molecular Biology and Genetics Department. He trained in pediatrics and pediatric hematology/oncology at Johns Hopkins and joined the faculty in 1990. Dr. Small’s laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. The investigations of FLT3 led Dr. Small and his team to discover drugs able to inhibit the cancer-generating activity of this important gene. His laboratory showed that a new class of drugs known as tyrosine kinase inhibitors could kill FLT3-affected cells, thus developing one of the earliest molecularly targeted cancer therapies. They then developed a test that enabled them to screen a host of additional kinase inhibitors and find several with great potency against FLT3. His group also led the first clinical trials investigating the use of a FLT3 inhibitor in adult relapsed and refractory FLT3 mutant AML, and determined how best to combine these drugs with chemotherapy. They also helped design the first pediatric trials of FLT3 inhibitors in pediatric AML and infant ALL. Dr. Small’s lab continues to investigate leukemic processes and the role of stem cells in governing the activities of the FLT3 gene in leukemia.
Alan David Friedman, MD

Alan David Friedman, MD

Dr. Friedman is the King Fahd Professor of Oncology and Professor of Pediatrics at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. He received his M.D. from the Harvard Medical School (1983), did his pediatric internship and residency at Boston Children's Hospital (1983-86), and completed a fellowship in pediatric hematology-oncology at Johns Hopkins (1986-89). As a fellow, he did post-doctoral research at the Carnegie Institution Department of Embryology located on the Johns Hopkins Homewood campus. Dr. Friedman has served on the Pediatric Oncology faculty at Johns Hopkins since 1989. His laboratory focuses on investigation of normal and abnormal blood-cell formation. Dr. Friedman also cares for children with cancer, specializing in the treatment of leukemia.
United States›Maryland›Baltimore›Elias Zambidis, MD

Partial Data by Infogroup (c) 2025. All rights reserved.

Yext

Partial Data by Foursquare.